A new drug called Xofigo for late stage prostate cancer is marketed by Bayer. Xofigo is a novel radiopharmaceutical called radium-223 dichloride. This drug for late stage prostate cancer is for use in men whose cancer has spread to the bones but no other organs. The medication is for patients with castration-resistant prostate cancer, which…
Immunotherapy in prostate cancer is becoming more prevalent because the treatment options are limited for patients with castrate-resistant prostate cancer, especially for patients who have not responded to docetaxel (Taxotere) therapy. Impact of prostate cancer Prostate cancer is a disease of older men for the most part. Few cases are diagnosed before the age of…
The incidence and death rates of certain cancers have typically been much lower among Asian populations when compared with those in North America, Europe, and Australia. Now a new study finds rising prostate cancer in Asians (including breast cancer as well) correlates with their transition to a Western diet. Let’s look at prostate cancer statistics….
Results of a four-year study show that men who took dutasteride (Avodart), a drug commonly prescribed for benign prostatic hyperplasia (BPH), were less likely to be diagnosed with prostate cancer. However, men taking dutasteride who did develop prostate cancer were more likely to have more deadly tumors—those with a high Gleason score—than men who took…
Provenge information gathering can be challenging since this immunotherapy treatment for prostate cancer has been getting a lot of press lately. It can be difficult to wade through the rhetoric about what Provenge (sipuleucel-T) is, what it can and cannot do for men who have prostate cancer, and how to pay for treatment. So we…
Results of a new study show that among men with prostate cancer who were treated with hormone therapy, those who were overweight or obese had a higher risk of worsening prostate cancer than did normal weight men. The research, conducted by researchers at Duke University Medical Center, was presented at the 2011 American Urological Association…
Provenge compared to Zytiga for treatment of metastatic prostate cancer has shown that both of these relatively new treatments can extend overall survival. This has led some men to ask whether they might be treated with both therapies. After all, combination treatment is a common approach for most cancers, including prostate cancer. Therefore, taking both…
A study presented in 2014 at the AACR-Prostate Cancer Foundation Conference on Advances in Prostate Cancer Research reported a surprising relationship between vigorous exercise and the shape of blood vessels found in prostate cancer tumors. Men who walked faster prior to a diagnosis of prostate cancer were found to have more regularly shaped blood vessels…
Provenge life expectancy is something you will want to know about following treatment with Provenge just as you would with any medical treatment for prostate cancer. In 2011 in the United States, there were 240,890 new cases of prostate cancer and 33,720 deaths from the disease. Most men are diagnosed early with only localized disease. However, other men…
For men who have localized or locally advanced prostate cancer, one of the main treatment options is external beam radiation therapy (EBRT). (Removal of the prostate, or radical prostatectomy, is the other main treatment choice.) External beam radiation therapy (EBRT) is the use of high-energy particles or rays to kill cancer cells. EBRT is typically…
Preparing for treatment with Provenge requires more steps than do other prostate cancer treatments. Let’s assume you, along with your healthcare team and your loved ones, have decided you are going to undergo treatment with Provenge. As you probably already know, Provenge (sipuleucel-T) is unlike all other drug treatments for prostate cancer: you don’t go…